Clinical Trials Directory

Trials / Completed

CompletedNCT01385150

Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia

Analysis of Serum 2-Hydroxyglutarate (2HG) Levels, IDH Mutations and Clinical Outcome in Acute Myeloid Leukemia (AML)

Status
Completed
Phase
Study type
Observational
Enrollment
220 (actual)
Sponsor
Eastern Cooperative Oncology Group · Network
Sex
All
Age
17 Years – 60 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors identify and lean more about biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in blood samples from patients with acute myeloid leukemia.

Detailed description

OBJECTIVES: Primary * To determine if serum 2-hydroxyglutarate (2HG) is only detected in acute myeloid leukemia (AML) patients with isocitrate dehydrogenase (IDH) mutations. Secondary * To determine if the level of serum 2HG impacts leukemia-free survival (LFS). * To determine if the level of serum 2HG impacts overall survival (OS). * To determine if serum 2HG is undetectable at the time of documented clinical remission (CR) in IDH-mutated patients. OUTLINE: Archived serum samples are analyzed for 2-hydroxyglutarate expression by reverse-phase liquid chromatography coupled to mass spectrometry. Results are then compared with presence or absence of an IDH mutation, patients' clinical outcome, as well as age, sex, white blood cell count at diagnosis, platelet count, bone marrow blast percentage at diagnosis, circulating (serum) percentage at diagnosis, cytogenetic risk group, presence of FLT3, NPMN1, and/or TET2 mutations, specific IDH mutation, and randomization treatment group allocation.

Conditions

Interventions

TypeNameDescription
GENETICmutation analysis
GENETICprotein analysis
OTHERlaboratory biomarker analysis
OTHERliquid chromatography
OTHERmass spectrometry

Timeline

Start date
2012-01-03
Primary completion
2012-02-03
Completion
2012-02-03
First posted
2011-06-29
Last updated
2017-05-19

Source: ClinicalTrials.gov record NCT01385150. Inclusion in this directory is not an endorsement.